Search Results
Your search for all items matches 34717 pages
Showing 26451 - 26500SIDEBAR: Dating among Adolescents and Young Adults with Cancer
How do you tell somebody you are dating that you have cancer or that you may not be able to have children? These are among the issues explored in “Dating and Disclosure for the Cancer Patient,” part of a new book, Sexuality and Cancer, scheduled for release in the fall by Springer, New York. “The...
SIDEBAR: Don’t Expect Questions: Be Proactive with Younger Patients
It is unrealistic to expect adolescents and young adults with cancer to initiate questions about disease-related or or treatment-related issues that are troubling them, according to Bradley Zebrack, PhD, MSW, MPH, Associate Professor of Social Work at the University of Michigan, Ann Arbor....
Adolescent and Young Adult Patients Report Unmet Needs for Cancer Information and Psychosocial Support Services
In the News focuses on media reports that your patients may have questions about at their next visit. This continuing column will provide summaries of articles in the popular press that may prompt such questions, as well as comments from colleagues in the field. Psychosocial care needs are not...
Kidney Transplant Recipients Switching to Sirolimus Had Lower Risk of Secondary Squamous Cell Carcinomas
Kidney transplant recipients with at least one previous cutaneous squamous cell carcinoma decreased their risk of developing new cutaneous squamous cell carcinomas by switching from calcineurin inhibitors (cyclosporine or tacrolimus) to sirolimus (Rapamune) in a multicenter phase III study. New...
Taxane-induced Neuropathy Does Not Correlate with Improved Outcomes in Operable Breast Cancer
An analysis of 4,554 patients who received adjuvant weekly paclitaxel and other taxane-based regimens in the E1199 trial “demonstrated that taxane-induced peripheral neuropathy does not correlate with improved outcomes in patients with operable breast cancer,” investigators reported in the Journal...
New Agents That Improve Efficacy Can Also Increase Morbidity and Treatment-related Mortality
Newly approved anticancer drugs that lead to improvements in efficacy can also lead to increased morbidity and treatment-related mortality, according to a study in the Journal of Clinical Oncology. The investigators conducted a meta-analysis of 38 randomized controlled trials evaluating agents...
Updated for 2012: Cancer in Older Adults
Tell your patients about Cancer in Older Adults, Cancer.Net’s newly updated booklet for older adults and their family and friends. The content of the booklet is adapted from the ASCO University Module, Cancer Care for Older Patients. It provides information on the physical and emotional changes...
It’s Time to Get Ready for New Medicare Reporting Requirements
As if you didn’t already have enough to worry about, now add this: If your practice doesn’t meet the requirements of the Physicians Quality Reporting System (PQRS) and Electronic Prescribing (eRx) Incentive, you don’t just miss out on the bonuses the programs offered as incentive in recent years....
Conquer Cancer Foundation $10K Challenge: Multiply Your Donation’s Impact in September
The Foundation proudly announces its first-ever Conquer Cancer Foundation $10K Challenge. In September, a portion of online gifts to the Conquer Cancer Foundation of the American Society of Clinical Oncology will be matched by the generous support of Ariad Pharmaceuticals®. The Conquer Cancer...
ASCO Expert Panel Concludes Evidence Supports Physician Discussion of PSA Testing for Men with Longer Life Expectancies
ASCO has issued a new evidence-based provisional clinical opinion (PCO) on the use of prostate-specific antigen (PSA) testing for prostate cancer screening. To facilitate informed decisions, ASCO also released a new, detailed decision aid to help men and their physicians understand the risks and...
The 2013 Gastrointestinal Cancers Symposium Will Observe the Meeting’s 10-Year Anniversary
A decade after its start in 2003 with a few hundred attendees, the Gastrointestinal Cancers Symposium now boasts more than 3,000 participants from all over the world. The next implementation marks the meeting’s 10th anniversary. The 3-day meeting—to be held January 24–26 in San Francisco—is...
Chemotherapy plus Radiation Improved Progression-free Survival in Adults with Low-grade Glioma
Adult patients with supratentorial low-grade glioma who received chemotherapy with PCV (procarbazine [Matulane], lomustine [CeeNu], and vincristine) in addition to radiation therapy had improved progression-free survival but not overall survival compared to patients receiving radiotherapy alone,...
Coping with Liver Cancer
From the moment I had a partial hysterectomy in 2010, I started having unexplained bouts of nausea. My surgeon and even my primary care physician chalked it up to everything from the difficult 6-hour surgery I had just had to anxiety over a move I’d recently made from Connecticut to North Carolina. ...
Despite Challenges, Initiatives Bring Gradual Improvements to Cancer Care in Lebanon
Nagi S. El Saghir, MD, FACP, Professor of Clinical Medicine and Hematology-Oncology at the American University of Beirut, is the founding President of the Lebanese Society of Medical Oncology (LSMO). Dr. El Saghir has focused much of his research on the early detection, prevention, and treatment of ...
Preclinical Research Finds Gene that Permanently Stops Cancer Cell Proliferation
Researchers at Case Western Reserve University School of Medicine, Cleveland, have discovered a mutant form of the gene Chk1 that when expressed in cancer cells, permanently stopped their proliferation and caused cell death without the addition of any chemotherapeutic drugs.1 This study illustrates ...
Carfilzomib: New Drug with Accelerated Approval for Multiple Myeloma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication In July 2012, carfilzomib (Kyprolis) was granted...
Ipsilateral Radiotherapy for Cervical Lymph Node Metastases
Ipsilateral neck–only radiation therapy “demonstrated excellent locoregional control with no adverse effect on disease-free survival or overall survival” among patients with cervical metastases from an unknown primary site, according to a retrospective review of medical records from 46 patients...
Ongoing and Future Directions in Pancreatic Cancer Research
Margaret A. Tempero, MD, is a pioneer in pancreatic cancer treatment and research. She has long been a leader in the research and development of therapeutics for pancreatic ductal adenocarcinoma, particularly in studying investigational antibody-based therapies, developing the fixed-dose-rate...
Liposomal Vincristine Approved in Acute Lymphoblastic Leukemia
The FDA has approved vincristine sulfate liposome injection (Marqibo) to treat adults with Philadelphia chromosome–negative acute lymphoblastic leukemia (ALL). Administered once a week, liposomal vincristine is approved for patients whose leukemia has relapsed two or more times, or whose leukemia...
The Problem of Monitoring Remission
How wonderful it is that we now have to concern ourselves with survivorship issues! The ever-increasing success of cancer therapy means that more and more patients can look to a life beyond cancer diagnosis and treatment. But living with cancer creates its own problems. While treatment often may be ...
The Science of Resilience: Exploring the Process of Grieving from a New Perspective
How human beings cope with bereavement, loss, extreme adversity, and life-threatening illness has dominated the research interests of George A. Bonanno, PhD, Professor of Clinical Psychology, Teachers College at Columbia University, New York, for more than 20 years. In his book, The Other Side of...
No Advantage to Longer Adjuvant Chemotherapy in Women with Early Breast Cancer: CALGB 40101 Trial
The ideal duration of adjuvant therapy for women with lower-risk primary breast cancer remains unknown. The National Surgical Adjuvant Breast and Bowel Project (NSABP) B-15 trial, reported more than 20 years ago, found no difference in outcomes between six cycles of cyclophosphamide, methotrexate,...
Meetings Calendar
September 1st Multidisciplinary Symposium: Molecular Oncology: From Laboratory Bench to MedicineSeptember 17-22 • Kyiv, Ukraine For more information: http://rmd.org.ua/en Cancer Vaccines: Advances in Design, Therapy and EfficacySeptember 19-20 • London, United Kingdom For more information:...
Letter to the Editor: Dr. Ablin’s Reply
Given my explanation and widely publicized opinion on the improper use of the prostate-specific antigen (PSA) test for screening asymptomatic men for prostate cancer—most recently expressed in a feature article in The ASCO Post (August 15, 2012)—I was pleased to read that Drs. James Mohler and...
Letter to the Editor: More Thoughts on PSA
An article that appeared in the August 15 issue of The ASCO Post (“Rethinking the Role of PSA Screening in Public Health”) contains false statements about the discovery of prostate-specific antigen (PSA) and its effectiveness as a test for early detection of prostate cancer. Contrary to what’s...
High-cost Imaging Used Frequently in Elderly with Stage IV Cancer
Patients with stage IV breast, colorectal, lung, and prostate cancers undergo frequent high-cost imaging procedures throughout the continuum of their care, and rates of imaging have steadily increased, according to an analysis of claims from the Surveillance, Epidemiology, and End Results...
Patients with Unresectable Metastases Can Be Spared Noncurative Resection of Intact Primary Tumor
Patients with surgically unresectable metastatic colon cancer and an asymptomatic intact primary tumor can be spared initial noncurative resection of their intact primary tumor, National Surgical Adjuvant Breast and Bowel Project (NSABP) C-10 trial investigators reported in the Journal of Clinical...
Cetuximab Dose Escalation May Increase Responses among Patients with Mild or No Initial Skin Reactions
Escalating the dose of cetuximab (Erbitux) among patients with metastatic colorectal cancer who developed no or mild skin reactions on standard-dose cetuximab plus irinotecan “seemed to lead to an increase in response rate” as well as in the disease-control rate, according to a phase I/II study...
Enzalutamide Significantly Prolonged Survival in Men with Castrate-resistant Metastatic Prostate Cancer
“Enzalutamide significantly prolonged the survival of men with metastatic castration-resistant prostate cancer after chemotherapy” in an international phase III, double-blind, placebo-controlled trial, investigators reported in The New England Journal of Medicine. Median overall survival, the...
Being Well Informed Helped Me Cope with Breast Cancer
I had been putting off getting a screening mammogram for a few years. When I finally made an appointment in March 2011 and was told that I needed a follow-up sonogram because the test had picked up a suspicious-looking mass in my right breast, I knew I was in trouble. A biopsy of the tumor showed...
SIDEBAR: Unique Considerations for Radiation Exposure in Children
There are three “unique considerations” for radiation exposure in children, according to Radiation Risks and Pediatric Computed Tomography (CT): A Guide for Health Care Providers, an educational leaflet for health-care providers that was developed by the NCI: Children are considerably more...
SIDEBAR: Expect Questions from Parents
Results of a study finding that exposure to radiation from multiple CT scans in childhood can triple the risk of leukemia and brain tumors may cause some parents to question the overall benefit of CT scans and to directly question physicians. “The three key questions that parents can ask are: (1)...
CT Scans in Childhood Can Triple Risk of Leukemia and Brain Cancer Later in Life, Study Finds
In the News focuses on media reports that your patients may have questions about at their next visit. This continuing column will provide summaries of articles in the popular press that may prompt such questions, as well as comments from colleagues in the field. Computed tomography scans with...
Researchers Awarded NCI Grants to Address ‘Provocative Questions’
Two scientists are among the first recipients of grants geared to answer “Provocative Questions” in cancer research, a new project funded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH). Cynthia Sears, MD, and Peter Searson, PhD, both of Johns Hopkins, will...
Getting the Right End-of-life Care: Coming to Terms with the Realities of Advanced Disease and Mortality
“Dying is at once a fact of life and a profound mystery.” That was the opening sentence of a 1997 Institute of Medicine report, Approaching Death: Improving Care at the End of Life, a much-needed jump-start in the national dialogue over identifying the barriers that impede the delivery of...
Ziv-aflibercept with FOLFIRI in Metastatic Colorectal Cancer
In August 2012, the antiangiogenic agent ziv-aflibercept (Zaltrap) was approved for use in combination with FOLFIRI (fluorouracil, leucovorin, irinotecan) for the treatment of metastatic colorectal cancer resistant to or progressing after an oxaliplatin-containing regimen.1,2 Approval was based on...
FDA Approves New Drug for Late-stage Prostate Cancer
The FDA has approved enzalutamide (Xtandi) to treat men with metastatic castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone. Approved for patients with prostate cancer previously treated with docetaxel, enzalutamide was...
New Indication for Cetuximab plus FOLFIRI to Treat EGFR-positive, Wild-type KRAS Metastatic Colorectal Cancer
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication In July 2012, cetuximab (Erbitux) was approved for use...
FDA Grants Priority Review to Supplemental New Drug Application for Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer
Janssen Research & Development, LLC, announced that the FDA has granted Priority Review to the supplemental New Drug Application (sNDA) for abiraterone acetate (Zytiga) administered in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer ...
Inaugural Quality Care Symposium Will Detail How to Pioneer Successful Quality Initiatives in Your Practice
Over the past 10 years, Wilshire Oncology Medical Group of La Verne, California, has reengineered itself so that all processes—from front-desk operations at all eight locations to the 10 oncologists’ interactions with patients and payers—capture quality data that can be used for robust benchmarking ...
A Great IDEA: Supporting the Next Generation of Oncology Leaders in Low- and Middle-income Countries
Leadership has been cited as a critical success factor in improving access to cancer care in low- and middle-income countries.1 Effective clinical leaders in these countries can be transformative by supporting the development of cancer treatments to meet the needs of their patients, by advocating...
What the Latest Breast Cancer News Means For Patients
Direct your patients to www.cancer.net/breastsymposium to learn about the research highlighted at the 2012 Breast Cancer Symposium in the special online newsletter, Cancer Advances: News for Patients from the 2012 Breast Cancer Symposium. In addition, your patients can listen to a podcast of the...
Kidney Cancer Association Works with Conquer Cancer Foundation to Stimulate Breakthrough Research
For any nonprofit cancer organization, a key challenge is how to balance the enormous task of supporting cancer patients with the latest information about current treatments while helping to advance the search for new breakthroughs in therapeutic options. For the past 6 years, the Kidney Cancer...
All Oncology Care Practices Urged to ‘Be Counted’ in Groundbreaking Census
The National Oncology Census, sponsored by the American Society of Clinical Oncology (ASCO), represents the first-ever attempt to capture comprehensive, real-time data on the state of oncology practice in the United States. ASCO is urging all U.S. oncology practices—representing oncologists in...
Genitourinary Cancers Symposium Still Intimate Despite Record Growth
Despite its exponential growth since launching in 2007—from 1,450 attendees then to a record 2,530 last year—the Genitourinary (GU) Cancers Symposium remains an inviting meeting that feels small, accessible, and comfortable. And that’s the perfect blend for networking, said Jeff Michalski, MD,...
TRIM27 as Target in Cancer Development
The tripartite motif family protein 27 (TRIM27) is a transcriptional repressor that reduces induction of cell senescence by retinoblastoma-associated protein (RB1). High levels of TRIM27 expression occur in several human cancers and have been associated with poor prognosis in breast and endometrial ...
VEGF Pathway Biomarker for Outcome with Bevacizumab
No biomarkers are available to guide patient selection for treatment with the anti-VEGF monoclonal antibody bevacizumab (Avastin). Lambrechts and colleagues from VIB and KULeuven and University Hospital Gasthuisberg, Belgium, and F. Hoffmann-La Roche in Basel, Switzerland, have identified a locus...
Evolutionary Pathways in BRCA1-associated Breast Tumors
BRCA1 germline mutations are associated with elevated risk of breast and ovarian cancers, and somatic loss of the wild-type BRCA1 allele has been thought to be a rate-limiting initiating step in tumor development. BRCA1-associated breast tumors acquire additional somatic alterations during...
Metastasis Promoted by Cleaving and Inhibiting Proapoptotic Effect of von Willebrand Factor
Mochizuki and colleagues from Keio University in Tokyo, the Chemo-Sero-Therapeutic Research Institute in Kumamoto, and RIKEN in Saitama have shown that von Willebrand factor has proapoptotic effects and that a disintegrin and metalloproteinase 28 (ADAM28) promotes metastasis by cleaving and...
Predictive Markers for Outcome with Pazopanib in Metastatic Renal Cell Cancer
Several targeted drugs are approved for treatment of metastatic renal cell cancer, but no validated biomarkers are available for prediction of clinical outcome of treatment with these agents. In a recent study, Tran and colleagues from The University of Texas MD Anderson Cancer Center in Houston,...
